
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral syrup containing docusate sodium, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing docusate is listed. Products containing it are filed in the directory as over-the-counter monograph drugs and unapproved drugs, in capsule, tablet, liquid and solution forms. None of the listed products containing docusate is in syrup form.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Docusate sodium is a surfactant stool softener, taken by mouth or used rectally, that a pharmacy may compound when a prescriber orders it.
Docusate sodium (dioctyl sulfosuccinate) is a surfactant laxative, or emollient stool softener. It lowers the surface tension between the oil and water in stool, which lets water and fats move into the stool so it becomes softer and easier to pass. No FDA-approved (NDA or ANDA) docusate product exists; single-ingredient docusate is sold over the counter, for example as Colace soft gels, filed on DailyMed as an OTC monograph drug and labeled as a stool softener to relieve occasional constipation. StatPearls notes that docusate has no FDA-approved indications. MedlinePlus describes stool softeners as a short-term option for people who should avoid straining. A prescriber might order docusate compounded in a form or strength not sold over the counter, or without a particular excipient. Compounded preparations are not FDA-approved and require a prescription.
Docusate has no boxed warning. The Colace label says not to use it with mineral oil unless a doctor tells you to; StatPearls explains that docusate may increase absorption of mineral oil. Ask a doctor before use if you have stomach pain, nausea, vomiting, or a sudden change in bowel habits lasting over 2 weeks. Stop and ask a doctor if you have rectal bleeding or no bowel movement after using it, which could signal a serious condition, or if you need it for more than 1 week. Possible side effects include stomach cramps, nausea, and throat irritation with liquid forms; call your doctor right away for rash, hives, trouble breathing or swallowing, fever, vomiting, or stomach pain. StatPearls notes that overuse can lead to laxative dependence. LactMed states docusate is minimally absorbed and unlikely to reach breast milk. If pregnant or breastfeeding, talk to your prescriber or pharmacist.
Docusate is an anionic surfactant that reduces surface tension at the oil and water interface of stool, allowing water and lipids to penetrate the stool mass (StatPearls). StatPearls and LactMed describe it as minimally absorbed from the gastrointestinal tract. Manufactured products are OTC: the Colace soft gel SPL is filed as an OTC monograph drug (M007) with the use "relieves occasional constipation," generally producing a bowel movement in 12 to 72 hours per the label. StatPearls states docusate has no FDA-approved indications, and describes oral, rectal (enema and suppository) and ear drop administration, including use to soften cerumen before removal; these uses are not FDA-approved indications. StatPearls also describes weak evidence for docusate in opioid-induced constipation. Cautions per StatPearls include intestinal obstruction, appendicitis symptoms, acute abdominal pain, fecal impaction, and gasping syndrome in neonates from benzyl alcohol in some formulations. Monitor for laxative overuse, which can cause fluid and electrolyte losses with hypokalemia, hypomagnesemia and non-anion gap metabolic acidosis. Dosing is per prescriber.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup provided, not a household spoon. Take it by mouth as directed on the label. Rinse the measuring device and recap the bottle after each dose.
Syrups are aqueous preparations. Under USP <795>, a preserved syrup usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label shows whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally